CLINICAL TRIAL

Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2025-06-10
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University of California San Francisco

Watch author

Derived topics and classifications

psilocybin psilocin Healthcare Workers Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric DisordersJournal of Pharma Insights and Research. · 2025-10-05 Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics.Journal of psychopharmacology (Oxford, England) · 2025-09-01 Unmixing the psychedelic connectome: Brain network traits of psilocybinNetwork Neuroscience · 2026-07-02 DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in ZebrafishMolecules · 2026-06-18 New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants.Birth defects research · 2026-05-01 Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping reviewJournal of Psychedelic Studies · 2026-03-09 Mushroom-Derived Carbon Nanosheets for Efficient Photothermal De-Icing Applications.Langmuir: the ACS journal of surfaces and colloids · 2026-03-03 Psilocin as a Broad Inhibitor of CYP450 Enzymes: Integrated In Vitro and In Silico EvidenceInstituto Politécnico do Porto · 2026-02-25